Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis
- 10 May 2021
- journal article
- research article
- Published by Wiley in Emergencias
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Reversal of direct oral anticoagulants: Guidance from the Anticoagulation ForumAmerican Journal of Hematology, 2019
- Anticoagulation in Atherosclerotic DiseaseHämostaseologie, 2018
- 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary SyndromesJournal of the American College of Cardiology, 2014
- Pros and cons of new oral anticoagulantsHematology, 2013
- Apixaban with Antiplatelet Therapy after Acute Coronary SyndromeThe New England Journal of Medicine, 2011
- Novel Oral Factor Xa and Thrombin Inhibitors in the Management of ThromboembolismAnnual Review of Medicine, 2011
- Dabigatran versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2009
- Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary SyndromeCirculation, 2009
- Clinical End Points in Coronary Stent TrialsCirculation, 2007
- Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.Circulation, 1987